# Federal Dupixent lymphoma lawsuits centralized in New Jersey

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-06-04; updated 2026-06-04. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/dupixent-mdl-3180

The Judicial Panel on Multidistrict Litigation centralized federal lawsuits alleging that Dupixent (dupilumab), a biologic often prescribed for atopic dermatitis, caused or accelerated cutaneous T-cell lymphoma. The cases are now MDL No. 3180 before Judge Zahid N. Quraishi in the District of New Jersey.

**Why it matters.** Pretrial proceedings for federal Dupixent cases now run before one judge; the Panel reported 35 actions pending as of September 1, 2026.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment. Dupixent remains approved by the U.S. Food and Drug Administration.

## Sources

1. [JPML transfer order](https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3180-Transfer_Order-5-26.pdf)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/dupixent-mdl-3180#ask. General information, not legal advice.